Medicine and Dentistry
Vitreoretinal Surgery
100%
Proliferative Diabetic Retinopathy
94%
Diabetic Retinopathy
91%
Optical Coherence Tomography Angiography
81%
Medical Student
63%
Ophthalmology
60%
Oximetry
57%
Surgeon
57%
Branch Retinal Vein Occlusion
56%
Oxygen Saturation
55%
Systematic Review
52%
Treatment Response
52%
Aflibercept
41%
Cataract Surgery
37%
Disease
36%
Laser Coagulation
35%
Wet Macular Degeneration
33%
Low Level Laser Therapy
32%
Retina Neovascularization
30%
Screening
26%
Medical Procedures
26%
Twin Study
26%
Migraine
26%
Visual Field
26%
Heritability
26%
Cohort Analysis
26%
Dizygotic Twins
26%
Monotherapy
26%
Clinical Trial
26%
Diagnosis
26%
Macular Edema
26%
Blood Vessel
26%
Ranibizumab
26%
Angiography
26%
Optical Coherence Tomography
26%
Prospective Study
24%
Odds Ratio
22%
Monozygotic Twins
19%
Color Vision
17%
Sleep Deprivation
17%
Contrast Sensitivity
17%
Vasculotropin Inhibitor
17%
Fluorescein Angiography
16%
Psychomotor Performance
13%
Heredity
13%
Oxygen Consumption
13%
Cross Sectional Study
12%
Wilcoxon Signed Ranks Test
12%
Intravitreal Administration
11%
Diabetes
11%
Nursing and Health Professions
Vitreoretinal Surgery
79%
Systematic Review
52%
Optical Coherence Tomography Angiography
52%
Medical Student
44%
Proliferative Diabetic Retinopathy
41%
Surgical Simulator
35%
Laser Coagulation
30%
Diabetic Retinopathy
26%
Correlation Coefficient
26%
Vascular Disease
26%
Cross-Sectional Study
26%
Treatment Response
26%
Photography
26%
Disease
26%
Forceps
17%
Sleep Deprivation
17%
Fluorescence Angiography
16%
Wilcoxon Signed Ranks Test
12%
Patient Safety
8%
Virtual Reality
8%
Thromboplastin
8%
Patient with Diabetes
7%
Diabetes Mellitus
7%
Embase
7%
Meta Analysis
7%
Cochrane Library
7%
Pharmacology, Toxicology and Pharmaceutical Science
Wet Macular Degeneration
60%
Diabetic Retinopathy
56%
Diabetic Macular Edema
38%
Aflibercept
34%
Clinical Trial
30%
Cohort Study
26%
Proliferative Diabetic Retinopathy
26%
Monotherapy
26%
Migraine
26%
Ranibizumab
26%
Branch Retinal Vein Occlusion
26%
Vasculotropin Inhibitor
19%
Side Effect
13%
Adverse Event
12%
Intravitreal Administration
11%
Prospective Study
9%
Randomized Controlled Trial
9%
Macular Edema
8%
